Women’s Health Capital Review: October 2026

October’s Women’s Health Capital Review tracks seven venture rounds totalling about $49M highlighting where capital is flowing and what the latest deals reveal about investment in women’s health.
The Precision Premium: An Investment Framework for Women’s Health and Precision Healthcare

How can better understanding of biology, clinical needs and lived experience create better healthcare and investable value? Maryann Selfe introduces the Precision Premium framework.
Women’s Health Capital Review: September 2026

September’s Women’s Health Capital Review tracks 18 funding rounds totaling US$287.8 million, highlighting where capital is flowing and what the latest deals reveal about investment in women’s health.
Women’s Health Data Infrastructure: A Critical Missing Link

Wearables are collecting more data about women’s bodies than ever before. Maryann Selfe explains why the opportunity in women’s health data infrastructure lies in interpreting wearable signals, validating them clinically and turning them into better healthcare decisions.
Women’s Health Investing: Direct Investments vs Specialist Funds

Women’s health investing can be accessed through direct investments, specialist funds or a combination of both. Maryann Selfe examines the trade-offs across expertise, diversification, access and portfolio risk.
Women’s Health Investment Opportunity: What Investors Should Know

The women’s health investment opportunity is expanding as science and technology turn longstanding healthcare gaps into scalable markets. Maryann Selfe examines the commercial evidence and the questions investors should consider before allocating capital.
How to Invest in Women’s Health: An Institutional Investor’s Guide

Maryann Selfe explains how family offices and institutional investors can invest in women’s health through funds, direct deals and diversified platforms.
How AI Is Reshaping Private Capital Markets

Artificial intelligence is reshaping private capital markets. Explore how capital concentration is changing venture capital, private equity and institutional investing.
When the Playbook Stops Working: What the ECB’s Dilemma Reveals About Europe’s Ageing Economy and the Women’s Health Opportunity

Europe’s central banks are confronting inflation driven by geopolitics, ageing populations and structural change rather than traditional demand cycles. The same forces exposing the limits of monetary policy are reshaping healthcare systems—and creating one of the largest overlooked investment opportunities in women’s health.
Gilead’s $11.5B Bet: What Two Companies Saw in One Week

Gilead and UCB deployed $3B+ on similar autoimmune drugs within days. What this pharmaceutical investment convergence signals for institutional investors tracking women’s health.